

Exhibit 55

Quarterly Compliance Report to Board of Directors 1Q2014

Bert Weinstein
Vice President, Corporate Compliance
May 15, 2014



U.S. - 118



Compliance Summary for 1Q2014

Purdue continues to have excellent systems and processes in place to prevent and detect violations, and to remediate issues before they become major.

No significant compliance issues to date in 2014

Company-Wide Compliance Scorecard YTD score is 3.14 out of 3.5

- in-line with previous year's scores (2011= 3.09; 2012= 3.12; 2013 = 3.15)



U.S. - 119

Government Action Continues




- Government pharma fraud and abuse prosecutions continue apace, with aggressive plaintiffs bar “supplementing” limited government resources - - *\$8 billion recovered* in 2013 by Federal and state governments

- 2014 Significant Federal Activity
 - Astellas – off-label pediatric promotion of anti-fungal - 4/2014
 - Teva – kick-backs paid to induce Rx’s of anti-psychotic - 3/2014
 - Endo – off-label promotion of Lidoderm – 2/2014
 - Novartis – Federal suit for payments to specialty pharmacy – 1/2014



U.S. - 120

Top Compliance Risks 1Q14



- High - 1
- Medium - 12
- Low - 22



U.S. - 121

Top Compliance Risks, and Mitigation



We prioritize compliance activities based on relative risks

Managed Care (High Risk)

- Increased government scrutiny, affecting large number of lives, significant generic pressure on formulary listing; Managed Care seeking aggressive rebate levels and implementing Prior Authorizations for most opioids
- Mitigation includes auditing and monitoring by Corporate Compliance, training, guidelines and procedures

Government Price Reporting (Medium Risk)

- Continued focus by CMS and OIG on accurate price reporting, with highly complex regulations
- Mitigation includes oversight by Law and EAC, third party audits, policies and procedures



Top Compliance Risks, and Mitigation



Sunshine Act (Medium Risk)

- Receiving clean data from CROs, and numerous data inaccuracies in meals provided to HCPs (both home office and sales force) are still problematic
- Mitigation includes increased training and business manager accountability

Appropriate Promotion (Medium Risk)

- Includes Sales Representative, Third-Party Activities, Speaker Programs, and Social Media, with risk around inappropriate promotion around abuse potential, comparisons to other products, convenience / superiority claims
- Mitigation includes auditing and monitoring by Corporate Compliance, training, guidelines, and procedures



Compliance Audits Completed - 2014



Medical Information Requests (Low Risk)

- To provide a level of assurance that inquiries received by Medical Services were not solicited and/or confirm whether or not improper promotion may have occurred by Sales Representatives
- No Critical Findings; positive practice noted around detection of potential solicitation of inquiries

Call Note Follow-Up Audit (Medium Risk)

- Follow-up to 2010 Compliance audit, to verify that District Managers were properly reviewing, coaching, and documenting any issues discovered in call notes
- No Critical Findings; 2 Major Findings (unclear call notes, missed AEs); improvements shown from previous audit



Compliance Audits Completed - 2014



Material Review (Medium Risk)

- To assess expired status of materials in the APRIMO system
- Report pending - No Critical Findings; 1 Major Finding (~5% of materials were expired but still in use); several positive practices were noted

Field Contact Report Audits (Medium Risk)

- One random audit and one for-cause audit (7 DMs)
- To assess whether District Managers were accurately documenting compliance issues on Field Contact Reports and appropriately evaluating Sales Representative compliance
- Report pending - No Critical Findings; 3 Major Findings (timeliness of expense reporting, poor call notes, accuracy of FCR documentation)



Sunshine Act Update



- Phase I registration timely, with filings on behalf of six entities:
 - Purdue Pharma L.P.
 - Purdue Neuroscience Company
 - Purdue Pharma of Puerto Rico
 - Purdue Pharma Products L.P.
 - Purdue Transdermal Technologies L.P.
 - Rhodes Pharmaceuticals

- Phase II filing anticipated to begin late May-late June (tbd)
 - 16,559 unique HCPs and Teaching Hospitals to be reported
- Data publication anticipated September 30, 2014 (?)



U.S. - 126


Sunshine Act Update



Total Reported in Phase I: \$10,223,108.93

| Open Payments Report | Total Aggregated Spend \$ | Total # of Records | Total # of Covered Recipients |
|----------------------|---------------------------|--------------------|-------------------------------|
| Research Payments | \$6,451,951.85 | 2,943 | 315 |
| General Payments | \$3,771,157.08 | 25,329 | 16,244 |

Type of Spend*



* As of May 5, 2014; subject to change.

U.S. - 127

Top 15 Physicians*



| Last Name | First Name | State | Recipient Type | Spend Amount |
|---------------|------------|-------|----------------|----------------|
| Apseloff | Glen | OH | MD | \$1,502,280.28 |
| Reiner | David | NJ | MD | \$623,494.00 |
| Pellechi | Thomas | CT | MD | \$147,345.95 |
| Buchanan | William | TX | MD | \$126,000.00 |
| Chipman II | Howard | FL | MD | \$112,578.02 |
| Hale | Martin | FL | MD | \$83,967.43 |
| Dawson | Gary | GA | MD | \$65,957.29 |
| Buynak | Robert | IN | MD | \$64,200.49 |
| Cucchiaro | Giovanni | CA | MD | \$62,102.92 |
| Pergolizzi Jr | Joseph | FL | MD | \$57,247.61 |
| Surowitz | Ronald | FL | MD | \$56,942.54 |
| Taber | Louise | AZ | MD | \$48,812.01 |
| Ratzman | David | IN | MD | \$39,176.13 |
| Schertzinger | Howard | OH | MD | \$37,507.76 |
| Simon | Steven | KS | MD | \$36,452.03 |



* As of May 5, 2014; subject to change.